Journal of Pediatric Urology
Volume 4, Issue 6 , Pages 428-433 , December 2008

Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity

  • Pramod P. Reddy

      Affiliations

    • Division of Pediatric Urology (MC-5037), Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45299-3039, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 636 6745; fax: +1 513 636 6753.
    • ,
  • Niels G. Borgstein

      Affiliations

    • Pfizer Worldwide Research, New London, CT, USA
    • ,
  • Rien J.M. Nijman

      Affiliations

    • Department of Urology, University Medical Centre Groningen, Groningen, The Netherlands
    • ,
  • Pamela I. Ellsworth

      Affiliations

    • Division of Urology, Brown University/University Urological Associates, Inc., Providence, RI, USA

Received 13 September 2007 ,Accepted 13 May 2008.

References 

  1. van Gool JD, Dik P, de Jong TP. Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatr. 2001;160:414–420
  2. Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction. Curr Opin Urol. 2002;12:473–477
  3. Madersbacher HG. Neurogenic bladder dysfunction. Curr Opin Urol. 1999;9:303–307
  4. Buyse G, Verpoorten C, Vereecken R, Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol. 1998;160:1084–1087discussion 92
  5. Franco I, Horowitz M, Grady R, Adams RC, De Jong TP, Lindert K, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol. 2005;173(1):221–225
  6. Goessl C, Knispel HH, Fiedler U, Härle B, Steffen-Wilke K, Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology. 1998;51(1):94–98
  7. Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 1997;157:638–640
  8. Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol. 1996;156:753–756
  9. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327:195–207
  10. Ayan S, Kaya K, Topsakal K, Kilicarslan H, Gokce G, Gultekin Y. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. BJU Int. 2005;96(3):411–414
  11. Bolduc S, Upadhyay J, Payton J, Bägli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure. BJU Int. 2003;91(4):398–401
  12. Goessl C, Sauter T, Michael T, Bergé B, Staehler M, Miller K. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000;55(3):414–418
  13. Munding M, Wessells H, Thornberry B, Riden D. Use of tolterodine in children with dysfunctional voiding: an initial report. J Urol. 2001;165:926–928
  14. Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol. 2005;173:1334–1339
  15. Ellsworth PI, Borgstein NG, Nijman RJ, Reddy PP. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response. J Urol. 2005;174:1647–1651discussion 51
  16. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol. 1998;34:148–153

PII: S1477-5131(08)00317-3

doi: 10.1016/j.jpurol.2008.05.003

Journal of Pediatric Urology
Volume 4, Issue 6 , Pages 428-433 , December 2008

Article Tools

* Image Usage & Resolution